Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) on July 10, 2018. The report details corporate governance actions taken following the Company's 2018 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Charter Amendment: The Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, increasing authorized common stock from 100,000,000 to 120,000,000 shares, effective July 10, 2018.
- Equity Plan Amendment: Stockholders approved an amendment to the 2014 Equity Incentive Plan to increase the maximum number of shares authorized for issuance by 6,000,000 shares.
- Reverse Stock Split Authority: Stockholders approved an amendment authorizing the Board of Directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-15. The specific ratio and implementation timing are to be determined by the Board.
- Director Elections: Stephen From and Peter Greenleaf were elected as Class III Directors for a three-year term.
- Auditor Ratification: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosures associated with the proposed reverse stock split. The reverse stock split authority grants the Board discretion to determine the exact ratio and whether to implement the split, which represents a potential future capital structure change.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and implementation date, as the Board retains discretion to determine these details post-approval.
- Confirm the updated total number of authorized shares (120,000,000) in subsequent filings.
- Review the amended 2014 Equity Incentive Plan to understand the impact of the additional 6,000,000 authorized shares on dilution.
- Monitor future filings for the actual execution of the reverse stock split, if the Board decides to proceed.